Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jian-Ge

Showing results (641-650 of 657) with videos related to

Pageof 66
Sort By:
European Radiology|June 27, 2023
Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching studyZhi-Cheng Jin, Bin-Yan Zhong, Jian-Jian Chen, et al.
European Journal of Medicinal Chemistry|October 15, 2018
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemiaXuesong Liu, Beilei Wang, Cheng Chen, et al.
Haematologica|November 27, 2025
Cell-free BRAF-V600E levels predict progression-free survival in children with Langerhans cell histiocytosis treated with dabrafenib and maintenance chemotherapyLei Cui, Dong Wang, Yun-Ze Zhao, et al.
Nature|September 6, 2019
Fast inflows as the adjacent fuel of supermassive black hole accretion disks in quasarsHongyan Zhou, Xiheng Shi, Weimin Yuan, et al.
Journal of Medicinal Chemistry|September 29, 2017
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AMLAoli Wang, Xixiang Li, Cheng Chen, et al.
Plos Medicine|November 23, 2005
CFH Y402H confers similar risk of soft drusen and both forms of advanced AMDKristinn P Magnusson, Shan Duan, Haraldur Sigurdsson, et al.
Cell Stem Cell|September 4, 2024
Human vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infectionLiuliu Yang, Yuling Han, Tuo Zhang, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Human Vascularized Macrophage-Islet Organoids to Model Immune-Mediated Pancreatic β cell Pyroptosis upon Viral InfectionLiuliu Yang, Yuling Han, Tuo Zhang, et al.
American Journal of Translational Research|May 5, 2017
Crizotinib synergizes with cisplatin in preclinical models of ovarian cancerXiao-Xiu Huang, Feng-Feng Xie, Li-Jiao Hou, et al.
Molecular Medicine (Cambridge, Mass.)|February 13, 2021
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinomaYing Zhu, Kun-Bin Ke, Zhong-Kun Xia, et al.
Pageof 66

Showing results (641-650 of 657) with videos related to

Sort By:
Pageof 66
European Radiology|June 27, 2023
Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching studyZhi-Cheng Jin, Bin-Yan Zhong, Jian-Jian Chen, et al.
European Journal of Medicinal Chemistry|October 15, 2018
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemiaXuesong Liu, Beilei Wang, Cheng Chen, et al.
Haematologica|November 27, 2025
Cell-free BRAF-V600E levels predict progression-free survival in children with Langerhans cell histiocytosis treated with dabrafenib and maintenance chemotherapyLei Cui, Dong Wang, Yun-Ze Zhao, et al.
Nature|September 6, 2019
Fast inflows as the adjacent fuel of supermassive black hole accretion disks in quasarsHongyan Zhou, Xiheng Shi, Weimin Yuan, et al.
Journal of Medicinal Chemistry|September 29, 2017
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AMLAoli Wang, Xixiang Li, Cheng Chen, et al.
Plos Medicine|November 23, 2005
CFH Y402H confers similar risk of soft drusen and both forms of advanced AMDKristinn P Magnusson, Shan Duan, Haraldur Sigurdsson, et al.
Cell Stem Cell|September 4, 2024
Human vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infectionLiuliu Yang, Yuling Han, Tuo Zhang, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Human Vascularized Macrophage-Islet Organoids to Model Immune-Mediated Pancreatic β cell Pyroptosis upon Viral InfectionLiuliu Yang, Yuling Han, Tuo Zhang, et al.
American Journal of Translational Research|May 5, 2017
Crizotinib synergizes with cisplatin in preclinical models of ovarian cancerXiao-Xiu Huang, Feng-Feng Xie, Li-Jiao Hou, et al.
Molecular Medicine (Cambridge, Mass.)|February 13, 2021
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinomaYing Zhu, Kun-Bin Ke, Zhong-Kun Xia, et al.
Pageof 66